Profiling Plasma Biomarkers, Particularly pTau217 and pTau217/Aβ42, and Their Relation to Cognition in Memory Clinic Patients
Journal of Neurochemistry · 2025-08 · 169 (8)
DOI: 10.1111/jnc.70182 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neurochemistry, online erschienen am 11.08.2025. Verfasst von Marco Bucci und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurobiology, Care Sciences and Society, Centre for Alzheimer Research, Division of Clinical Geriatrics, Karolinska Institutet, Stockho…. Hauptthemen laut MEDLINE: tau Proteins, Amyloid beta-Peptides, Cognitive Dysfunction, Peptide Fragments. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hjärnfonden, Vetenskapsrådet, Swedish State Support for Clinical Research.
Abstract (Originalsprache)
Alzheimer's disease (AD) is characterized by brain protein depositions, impaired synaptic transmission, and progressive cognitive decline. This clinical study, conducted at the tertiary memory clinic of Karolinska University Hospital in Stockholm, evaluates plasma pTau217 (in comparison to other plasma biomarkers) as a non‐invasive marker for predicting brain amyloid load and cognitive impairment. Uniquely, it integrates plasma biomarkers with cognitive profiling and amyloid PET to assess diagnostic utility across disease stages in a real‐world memory clinic setting. A total of 122 patients underwent extensive clinical examinations, including CSF analysis (used here for clinical diagnosis only), CT/MRI, neuropsychological (NP) testing ( n = 80) and blood biomarker measurements. Prior to PET imaging, 74 patients were diagnosed with MCI among other diagnoses (AD, other dementia, no dementia). Following PET, patients were reclassified into diagnostic groups: MCI Aβ− ( n = 29), MCI Aβ+ ( n = 19), AD ( n = 51), other dementias ( n = 11). ROC analysis evaluated the ability of plasma biomarkers to predict Aβ‐PET positivity. NP test z ‐scores were reduced into principal components (PCs) using PCA. Plasma pTau217 and pTau217/Aβ42 ratio were elevated in Aβ+ patients compared to MCI Aβ‐patients. The ratio distinguished MCI Aβ+ from AD and, together with pTau217, showed the highest predictive value for Aβ positivity in the MCI group among the biomarkers analyzed (AUC 92.8% and 91.4%). Plasma pTau217/Aβ42 ratio was associated with principal component PC2 (“memory encoding and recall”) in MCI Aβ+ ( ρ =0.64, p=0.01) and negatively correlated with RAVL retrieval (PC2) in the same group ( ρ =−0.57 and −0.6, p=0.028 and 0.017, respectively). Additionally, pTau217 correlated with the “Information” z ‐score (PC4) in both AD ( ρ = −0.50, p = 0.005) and MCI Aβ+ ( ρ = 0.53, p = 0.042). Plasma pTau217/Aβ42 might be a valuable predictor of brain amyloid pathology and a potential marker of domain‐specific cognitive impairment in AD. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurobiology, Care Sciences and Society, Centre for Alzheimer Research, Division of Clinical Geriatrics, Karolinska Institutet, Stockholm, Sweden.
- Turku PET Centre, Turku University Central Hospital and University of Turku, Turku, Finland.
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden.
- Medical Radiation Physics and Nuclear Medicine, Karolinska University, Stockholm, Sweden.
- Department of Neurology, Karolinska University Hospital, Stockholm, Sweden.
- Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
ORCID-Profile: Marco Bucci, Henrik Zetterberg, Agneta Nordberg
Förderung
- Hjärnfonden
- Vetenskapsrådet
- Swedish State Support for Clinical Research
- European Union's Horizon Europe research and innovation programme
- KI private bequest (A Nordberg)
- Fondation pour la Recherche sur Alzheimer
- Family Kaudert donation
- Region Stockholm KI CIMED
Zitieren
APA
Bucci, M., Almkvist, O., Bluma, M., Ashton, N. J., Savitcheva, I., Chiotis, K., Di Molfetta, G., Blennow, K., Zetterberg, H., & Nordberg, A. (2025). Profiling Plasma Biomarkers, Particularly pTau217 and pTau217/Aβ42, and Their Relation to Cognition in Memory Clinic Patients. Journal of Neurochemistry, 169(8). https://doi.org/10.1111/jnc.70182
Vancouver
Bucci M, Almkvist O, Bluma M, Ashton NJ, Savitcheva I, Chiotis K, et al. Profiling Plasma Biomarkers, Particularly pTau217 and pTau217/Aβ42, and Their Relation to Cognition in Memory Clinic Patients. Journal of Neurochemistry. 2025;169(8). doi:10.1111/jnc.70182
BibTeX
@article{Bucci2025,
author = {Bucci, Marco and Almkvist, Ove and Bluma, Marina and Ashton, Nicholas J and Savitcheva, Irina and Chiotis, Konstantinos and Di Molfetta, Guglielmo and Blennow, Kaj and Zetterberg, Henrik and Nordberg, Agneta},
title = {Profiling Plasma Biomarkers, Particularly pTau217 and pTau217/Aβ42, and Their Relation to Cognition in Memory Clinic Patients},
journal = {Journal of Neurochemistry},
year = {2025},
volume = {169},
number = {8},
doi = {10.1111/jnc.70182}
}
EUVIMED